Alyeska Investment Group, L.P. Glycomimetics Inc Transaction History

Alyeska Investment Group, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $122,875 - $153,549	-8,969 Reduced 1.95%	450,133 $6.48 Million
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $408,572 - $535,919	-27,927 Reduced 5.73%	459,102 $7.41 Million
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $5.21 Million - $8.22 Million	324,227 Added 199.15%	487,029 $7.9 Million
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $2.06 Million - $3.38 Million	-196,160 Reduced 54.65%	162,802 $2.73 Million
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $3.64 Million - $5.33 Million	358,962	358,962 $5.02 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.